ライフサイエンスコーパス: low-density

1 with outstanding mechanical performance and low density.

2 ee effects is difficulty in finding mates at low densities.

3 This low-density amorphous phase transforms into a high-densi

4 f current Fe-N-C is seriously limited by the low density and inferior exposure of active Fe-N(x) spec

5 s in TMDs, have been overlooked due to their low density and large structural variations.

6 llulose-based foams are a desirable class of low-density and porous materials for their potential in

7 rom their mechanically robust architectures, low density, and high accessible surface area.

8 glucose, serum lipids, triglycerides; total, low-density, and high-density cholesterol; and total bod

9 The analysis of the resistome by TaqMan low-density arrays revealed changes affecting primarily

10 in BALF cells was quantified by using TaqMan low-density arrays.

11 On the other hand, the permeability of low-density assemblies is a nonmonotonic function of the

12 cting for cells that proliferate normally at low density but continue to divide at high density.

13 mococcal behaviour following challenge, with low-density carriage representing the most stable ecolog

14 liferation more than macrophages cultured in low-density collagen.

15 Moderated mediation analyses show that, in low-density conditions, the benefits of inducing prosoci

16 udies in unconsolidated sediments due to the low density contrast between host sediment and trace fos

17 hort-pulse energy is coupled to a relatively low-density core with a radius of 70 mum.

18 face of the the high-density filament into a low-density corona surrounding the target.

19 high-density districts, whereas trips among low-density districts had lower volume with longer durat

20 various applications due to a combination of low density, ease of processing, and high thermal conduc

21 hat are the ground states of an interacting, low-density electron system?

22 In this metal-free and low-density environment, neutral helium atoms formed the

23 CD66b(+) CB low-density granulocytes (LDG) and CB normal-density gra

24 rophils and a subset of neutrophils known as low-density granulocytes (LDGs) have been implicated in

25 une disease characterized by the presence of low-density granulocytes (LDGs) with a heightened capaci

26 GS-AuNPs) with the same sizes, we found that low-density GS-AgNPs showed much higher vascular permeab

27 a reliable diagnostic test for asymptomatic low-density infections.

28 lling the harmful species population at some low density is needed, the agents should work together i

29 LDN were highly enriched in the low-density (LD) fraction of advanced lung cancer patien

30 s a result, total cholesterol, triglyceride, low-density lipid, high-density lipid, HbA1c (glycosylat

31 ements, hepatic metabolite analysis and very low density lipoprotein (VLDL)-TG secretion assays revea

32 high density lipoprotein cholesterol (HDL), low density lipoprotein cholesterol (LDL), or total chol

33 ree potential risk factors for CAD including low density lipoprotein cholesterol (LDL-c), high densit

34 index; waist circumference; total, high and low density lipoprotein cholesterol; triglycerides; gluc

35 aminases, fasting blood sugar, triglyceride, low density lipoprotein level, and lower high density li

36 Exported very-low density lipoprotein particles were isolated for unta

37 r increases of most components of VLDL (very low density lipoprotein) subparticles.

38 lipoprotein E, lipoprotein(a), oxidized LDL (low density lipoprotein)'s and large LDL particles, as w

39 mature IHD, and severe hypercholesterolemia (low-density lipoprotein >=190 mg/dl), overall prevalence

40 ed triglycerides (135-499 mg/dL), controlled low-density lipoprotein (41-100 mg/dL), and either estab

41 tein (HDL) <40 mg/dL, 2,078 subjects (5.3%); low-density lipoprotein (LDL) >130 mg/dL, 2,756 subjects

42 mia is characterized by an elevated level of low-density lipoprotein (LDL) cholesterol and an increas

43 This study investigated whether higher low-density lipoprotein (LDL) cholesterol and triglyceri

44 ffects of the intervention on SFA intake and low-density lipoprotein (LDL) cholesterol as well as the

45 in HMGCR, NPC1L1, and PCSK9 associated with low-density lipoprotein (LDL) cholesterol in a genome-wi

46 e is intimately linked to elevated levels of low-density lipoprotein (LDL) cholesterol in the blood.

47 as the same effect, per unit decrease in the low-density lipoprotein (LDL) cholesterol level, as the

48 inal fat, high total cholesterol level, high low-density lipoprotein (LDL) cholesterol level, high ve

49 dies point to an inverse correlation between low-density lipoprotein (LDL) cholesterol levels and ris

50 fractory hypercholesterolemia, who have high low-density lipoprotein (LDL) cholesterol levels despite

51 isiran might provide sustained reductions in low-density lipoprotein (LDL) cholesterol levels with in

52 d in the SWAI population and associated with low-density lipoprotein (LDL) cholesterol levels.

53 9, is widely used in adult patients to lower low-density lipoprotein (LDL) cholesterol levels.

54 ood pressure (SBP) of at least 140 mm Hg, or low-density lipoprotein (LDL) cholesterol of at least 13

55 ls have conclusively demonstrated that lower low-density lipoprotein (LDL) cholesterol results in few

56 BMI, -0.13 kg/m2 (-0.75 to 0.09), p = 0.093; low-density lipoprotein (LDL) cholesterol, 0.06 mmol/L (

57 Although SFAs increase low-density lipoprotein (LDL) cholesterol, in most indiv

58 in lipid traits in the UK Biobank (UKBB) for low-density lipoprotein (LDL) cholesterol, triglycerides

59 isease caused by markedly elevated levels of low-density lipoprotein (LDL) cholesterol.

60 saturated fatty acid (SFA) content to raise low-density lipoprotein (LDL) cholesterol.

61 tified ALK-1 as a high-capacity receptor for low-density lipoprotein (LDL) in endothelial cells that

62 Low-density lipoprotein (LDL) is heterogeneous, composed

63 Low-density lipoprotein (LDL) metabolism was studied in

64 btilisin/kexin type-9 (PCSK9) is a ligand of low-density lipoprotein (LDL) receptor (LDLR) that promo

65 the parent peptide and efficiently restored low-density lipoprotein (LDL) receptor levels and cleare

66 I-1) with its target enzymes bind tightly to low-density lipoprotein (LDL) receptor-related protein 1

67 comes in chronic hepatitis C (CHC) patients: low-density lipoprotein (LDL), high-density lipoprotein,

68 raits that include high-density lipoprotein, low-density lipoprotein (LDL), total cholesterol and tri

69 cholesterol from receptor-mediated uptake of low-density lipoprotein (LDL), which releases cholestero

70 ociations for cholesterol were strongest for low-density lipoprotein (LDL)-cholesterol, and remained

71 es from intestinal cells to the germline via low-density lipoprotein (LDL)-like particles to promote

72 (a)) covalently bound to apolipoprotein B of low-density lipoprotein (LDL).

73 Lowering low-density lipoprotein (LDL-C) and triglyceride (TG) le

74 Increased first-trimester low-density lipoprotein (LDL-C) concentration has been a

75 vity C-reactive protein (HsCRP) and oxidized low-density lipoprotein (Ox-LDL) in adolescents.

76 eride-rich lipoprotein (TRL) and small-dense low-density lipoprotein (sdLDL) particles are hallmarks

77 poprotein (LDL) cholesterol level, high very low-density lipoprotein (VLDL) cholesterol level, high t

78 ss, and adipocyte cell size and reduced very low-density lipoprotein (VLDL) levels, as compared with

79 ing pathway, thereby regulating hepatic very low-density lipoprotein (VLDL) secretion, and subsequent

80 HDL) subclasses and decreased levels of very low-density lipoprotein (VLDL), amino acids, and citrate

81 needed for lipoprotein synthesis, e.g., very low-density lipoprotein (VLDL), the precursor of circula

82 fish, red meat yielded greater decreases in low-density lipoprotein (WMD, -0.173 mmol/L; 95% CI, -0.

83 64 mmol/L; 95% CI, 0.144-0.383; P<0.001) and low-density lipoprotein (WMD, 0.198 mmol/L; 95% CI, 0.06

84 [OR] per one standard deviation decrease in low-density lipoprotein [LDL] cholesterol 0.76, 95% conf

85 years; 35% women; 70% with diabetes; median low-density lipoprotein [LDL] cholesterol level, 75.0 mg

86 response to sterile ligands such as oxidized low-density lipoprotein and damage-associated molecular

87 the AAPH-mediated oxidation of Caco-2 cells, low-density lipoprotein and deoxyribonucleic acid than t

88 e maternal circulation, maternal plasma very low-density lipoprotein and other lipoproteins are impor

89 tein B-containing lipoproteins, particularly low-density lipoprotein and remnant particles.

90 less high-density lipoprotein and more very-low-density lipoprotein and triglyceride particles in de

91 nd fatty acid compartmentalization; and very low-density lipoprotein assembly and secretion.

92 fying triglycerides >=135 and <500 mg/dL and low-density lipoprotein cholesterol >40 and <=100 mg/dL

93 s including diabetes mellitus, hypertension, low-density lipoprotein cholesterol >=100 mg/dl, and smo

94 es for secondary prevention in patients with low-density lipoprotein cholesterol >=70 mg/dL or non-hi

95 1% vs. 19% vs. 17%, respectively) and higher low-density lipoprotein cholesterol (117 vs. 107 vs. 103

96 with clinically evident atherosclerosis and low-density lipoprotein cholesterol (LDL-C) >=70 mg/dl o

97 us coronary intervention (PCI) with baseline low-density lipoprotein cholesterol (LDL-C) <=70 mg/dl a

98 -1.07]; P = .42) but resulted in higher mean low-density lipoprotein cholesterol (LDL-c) (2.86 vs 2.6

99 examine the rates of statin utilization and low-density lipoprotein cholesterol (LDL-C) achieved 1-y

100 ic disorder, which causes elevated levels of low-density lipoprotein cholesterol (LDL-C) and increase

101 LDL) secretion, and subsequently circulating low-density lipoprotein cholesterol (LDL-C) and triglyce

102 reased levels of total serum cholesterol and low-density lipoprotein cholesterol (LDL-C) at 6 months

103 to Target) showed the benefit of targeting a low-density lipoprotein cholesterol (LDL-C) concentratio

104 ular disease (CVD) increases with increasing low-density lipoprotein cholesterol (LDL-C) concentratio

105 cholesterolemia (FH) who are unable to reach low-density lipoprotein cholesterol (LDL-C) goals.

106 Low-density lipoprotein cholesterol (LDL-C) has been ass

107 Elevated low-density lipoprotein cholesterol (LDL-C) is associate

108 um-tolerated statin therapy, with a baseline low-density lipoprotein cholesterol (LDL-C) level >=70 m

109 s who do not achieve sufficient reduction in low-density lipoprotein cholesterol (LDL-C) level with a

110 h atherosclerotic cardiovascular disease and low-density lipoprotein cholesterol (LDL-C) levels >=70

111 type 9) inhibitors reduce lipoprotein(a) and low-density lipoprotein cholesterol (LDL-C) levels.

112 Although controlling low-density lipoprotein cholesterol (LDL-C) may improve

113 10 mg/dl [0.26 mmol/l]; p < 0.001), but not low-density lipoprotein cholesterol (LDL-C) or HDL-C, we

114 In this study, higher baseline levels of low-density lipoprotein cholesterol (LDL-C) predicted gr

115 Variants were weighted by associations with low-density lipoprotein cholesterol (LDL-C) using data f

116 density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were measure

117 High-sensitivity CRP and low-density lipoprotein cholesterol (LDL-C) were measure

118 igh-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglyc

119 a monoclonal antibody that robustly reduces low-density lipoprotein cholesterol (LDL-C), for the tre

120 2 prior pregnancy losses; total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-densit

121 effects are weaker on women than on men, for low-density lipoprotein cholesterol (LDL-C), uric acid (

122 type 9 inhibitor, lowers lipoprotein(a) and low-density lipoprotein cholesterol (LDL-C).

123 iglycerides to a greater extent than they do low-density lipoprotein cholesterol (LDL-C): fibrates, n

124 the percent change (baseline to week 24) in low-density lipoprotein cholesterol (LDL-C); secondary e

125 The main outcomes included low-density lipoprotein cholesterol (LDL-cholesterol), h

126 with or without ezetimibe and reductions in low-density lipoprotein cholesterol (LDLc) and C-reactiv

127 ts of lipid profile [total cholesterol (TC), low-density lipoprotein cholesterol (LDLc), high-density

128 18.17%; 95% CI -21.14%, -15.19%; p < 0.001), low-density lipoprotein cholesterol (MD -22.94%; 95% CI

129 oprotein cholesterol (TRL-C) and small-dense low-density lipoprotein cholesterol (sdLDL-C) concentrat

130 rol, HDL-C, non-HDL-C, direct and calculated low-density lipoprotein cholesterol [LDL-C], and apolipo

131 ine or aspartate aminotransferase, total and low-density lipoprotein cholesterol at baseline (<0.05),

132 re genome-wide significantly associated with low-density lipoprotein cholesterol based on 3203 subjec

133 urrent average levels with elevated total or low-density lipoprotein cholesterol concentrations.

134 crucial areas: targeting of statin dose (not low-density lipoprotein cholesterol goals), additional t

135 eciliter (1.52 to 5.63 mmol per liter) and a low-density lipoprotein cholesterol level of 41 to 100 m

136 The low-density lipoprotein cholesterol level was lower by a

137 e subtilisin kexin type 9 inhibitors) reduce low-density lipoprotein cholesterol levels and cardiovas

138 There was no relation between baseline low-density lipoprotein cholesterol levels and magnitude

139 ases in total, high-density lipoprotein, and low-density lipoprotein cholesterol levels compared with

140 ter high-density lipoprotein cholesterol and low-density lipoprotein cholesterol levels were associat

141 ns in continuous measures of blood pressure, low-density lipoprotein cholesterol levels, fasting gluc

142 Additional risk factors for CVD include low-density lipoprotein cholesterol levels, hypertension

143 been found to lower blood pressure (BP) and low-density lipoprotein cholesterol levels.

144 lycohemoglobin, systolic blood pressure, and low-density lipoprotein cholesterol than contemporary gu

145 entrations of triglyceride and low- and very-low-density lipoprotein cholesterol than controls, sugge

146 Recipient mice all had low levels of low-density lipoprotein cholesterol to promote plaque re

147 Mean estimated untreated low-density lipoprotein cholesterol was 206 mg/dL in tho

148 , fasting plasma triglycerides and high- and low-density lipoprotein cholesterol were measured in 34

149 , decades of research has established LDL-C (low-density lipoprotein cholesterol) as a causal factor

150 signaling plays an essential role in LDL-C (low-density lipoprotein cholesterol) homeostasis through

151 lipoprotein(a) is associated with increased low-density lipoprotein cholesterol, a family history of

152 LDL influence atherogenesis independently of low-density lipoprotein cholesterol, and high sensitivit

153 were adjusted for traditional risk factors, low-density lipoprotein cholesterol, and high-sensitivit

154 predictors of meeting trial goals for LDL-C (low-density lipoprotein cholesterol, goal <70 mg/dL) or

155 ss index, comorbidities and their treatment, low-density lipoprotein cholesterol, liver biochemistrie

156 ucose, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, systolic blood pres

157 Higher levels of apolipoprotein B, very-low-density lipoprotein cholesterol, triglycerides, digl

158 tergenic region near APOC1P1 associated with low-density lipoprotein cholesterol.

159 lycohemoglobin, systolic blood pressure, and low-density lipoprotein cholesterol.

160 e 1, 1.22; 95% CI, 1.01-1.48) independent of low-density lipoprotein cholesterol.

161 ished cardiovascular disease irrespective of low-density lipoprotein cholesterol.

162 of diabetes, high-density lipoprotein level, low-density lipoprotein level, history of hypertension,

163 Low low-density lipoprotein levels are associated with incre

164 n associated with increased mortality if low low-density lipoprotein levels contributed causally to s

165 re genotyped, and a genetic score related to low-density lipoprotein levels was calculated.

166 de polymorphisms known to be associated with low-density lipoprotein levels were genotyped, and a gen

167 c score, known to be directly related to low low-density lipoprotein levels, was associated with decr

168 sin/kexin type 9 (PCSK9), a key regulator of low-density lipoprotein metabolism, is induced by leptin

169 eater intracellular gaps and permeability to low-density lipoprotein or transmigrating THP-1 cells.

170 ion, followed by measurement of labeled very low-density lipoprotein palmitate via gas chromatography

171 22.94%; 95% CI -26.63%, -19.25%; p < 0.001), low-density lipoprotein particle number (MD -20.67%; 95%

172 .51%; 95% CI -3.75%, 0.74%; p = 0.189), very-low-density lipoprotein particle number (MD 3.79%; 95% C

173 Low-density lipoprotein particle size and high-density l

174 Low-density lipoprotein particles are taken up by cells

175 al cholesterol, low-density lipoprotein, and low-density lipoprotein particles, but no changes in mar

176 The apoE receptors low-density lipoprotein receptor (LDLR) and LDLR-related

177 a dramatic reduction in transcript levels of low-density lipoprotein receptor (LDLR) and of keratin g

178 fied sulfated glycosaminoglycans (sGAGs) and low-density lipoprotein receptor (LDLR) as host factors

179 Hepatic abundance of the low-density lipoprotein receptor (LDLR) is a critical de

180 btilisin/kexin type 9 (PCSK9), which reduces low-density lipoprotein receptor (LDLR) recycling and he

181 Low-density lipoprotein receptor (Ldlr)-knockout mice we

182 screen identified cholesterol uptake by the low-density lipoprotein receptor as essential for the gr

183 atp-binding cassette transporter (atp), and low-density lipoprotein receptor chaperone (ldlr), that

184 e-wide CRISPR-Cas9-based screen, we identify low-density lipoprotein receptor class A domain-containi

185 Five-week-old female low-density lipoprotein receptor deficient (LDL-R-/-) an

186 s a result of lower hepatic mRNA editing and low-density lipoprotein receptor expression, and higher

187 -2) is a protein structurally related to the low-density lipoprotein receptor family that displays a

188 Genetic ablation of Idol increases low-density lipoprotein receptor protein levels, which f

189 Moreover, LDLR (low-density lipoprotein receptor) deficient animals tran

190 We found that an extracellular fragment of low-density lipoprotein receptor-related protein 1 (LRP-

191 Here we show that the low-density lipoprotein receptor-related protein 1 (LRP1

192 g internalization of a SNX17 cargo receptor, low-density lipoprotein receptor-related protein 1 (LRP1

193 We hypothesized that LRP1 (low-density lipoprotein receptor-related protein 1) expr

194 We explored the role of low-density lipoprotein receptor-related protein 4 (LRP4

195 inding of y+z+ agrin to both heparin and the low-density lipoprotein receptor-related protein 4 (LRP4

196 Low-density lipoprotein receptor-related protein 4 (Lrp4

197 We demonstrate that the low-density lipoprotein receptor-related protein 4 (LRP4

198 spectroscopy and show that the co-receptor, low-density lipoprotein receptor-related protein 5 (Lrp5

199 ated the conditional knockout Wnt coreceptor low-density lipoprotein receptor-related protein 5 (Lrp5

200 nt signaling, we observed elevated levels of low-density lipoprotein receptor-related protein 5/6 (LR

201 Low-density lipoprotein receptor-related protein 6 (LRP6

202 rotein receptor-related protein 5 (Lrp5) and low-density lipoprotein receptor-related protein 6 (Lrp6

203 s duplication in Xenopus embryos, stimulated low-density lipoprotein receptor-related protein 6 (LRP6

204 Low-density lipoprotein receptor-related protein 6 encod

205 Reduction of frizzleds (fz), arrow (low-density lipoprotein receptor-related protein [LRP] 5

206 have been reported to be endocytosed by the low-density lipoprotein receptor-related protein-1 (LRP-

207 e N-methyl-d-aspartate receptor (NMDA-R) and low-density lipoprotein receptor-related protein-1 (LRP1

208 metabolism and insulin sensitivity through a low-density lipoprotein receptor-related protein-2 (LRP2

209 The proinflammatory cytokines and oxidized low-density lipoprotein significantly increased in the p

210 ke pattern, characterized by a high ratio of low-density lipoprotein to high-density lipoprotein, and

211 roduction of NO and reduced inflammation and low-density lipoprotein trafficking.

212 nd women and measuring the synthesis of very low-density lipoprotein triglyceride (VLDL-TG) palmitate

213 n, cellular adhesion, phagocytosis, oxidized low-density lipoprotein uptake, and expression of inflam

214 igh polygenic load of a large number of LDL (low-density lipoprotein) cholesterol (LDL-C) or triglyce

215 levation of aminotransferases, elevation of (low-density lipoprotein) cholesterol and steatosis in he

216 Pericardial fat volumes and LDL (low-density lipoprotein) cholesterol concentrations corr

217 has been directed to agents that reduce LDL (low-density lipoprotein) cholesterol, triglyceride, and

218 Early studies established that LDL (low-density lipoprotein) particles could act as efficien

219 ucing liver-specific degradation of the LDL (low-density lipoprotein) receptor combined with a 10-wee

220 Loss-of-function mutations in the LDL (low-density lipoprotein) receptor gene (LDLR) cause elev

221 LDL (low-density lipoprotein) that has accumulated in the art

222 ion in response to its ligand, oxidized LDL (low-density lipoprotein).

223 lls, phagocytic activity, uptake of oxidized low-density lipoprotein, and cytokine expression.

224 PCSK9, low-density lipoprotein, and high-density lipoprotein co

225 Small increases in total cholesterol, low-density lipoprotein, and low-density lipoprotein par

226 stolic and diastolic blood pressures, pulse, low-density lipoprotein, high-density lipoprotein, trigl

227 sterol dysregulation, generation of oxidized low-density lipoprotein, increased recruitment of hepati

228 poprotein B(100) (apoB), the core protein of low-density lipoprotein, is an autoantigen that drives t

229 lipid traits (high-density lipoprotein, HDL; low-density lipoprotein, LDL; triglycerides, TGs) with r

230 or changes in blood concentrations of total, low-density lipoprotein, or high-density lipoprotein cho

231 lated with the immune system, including very-low-density lipoprotein, vitellogenin, estrogen receptor

232 2 have decreased ABCA1 expression, increased low-density lipoprotein-cholesterol (LDL-C) and choleste

233 nt weight reduction and improved small dense low-density lipoprotein-cholesterol (sdLDL-C) profiles,

234 These mutations result in accumulation of low-density lipoprotein-derived cholesterol in late endo

235 Lipoprotein(a) is an atherogenic low-density lipoprotein-like particle and circulating le

236 knowledge, icosapent ethyl is the first non-low-density lipoprotein-lowering treatment that has been

237 varied between 0.09% (ALT) and 18.49% (LDL [low-density lipoprotein]) for the other traits.

238 siological shear stress with enzyme-modified low-density-lipoprotein (eLDL) with or without TNFalpha

239 :p.K405X, which is associated with decreased low-density-lipoprotein (LDL) cholesterol (P = 1.3 x 10(

240 the plasma membrane where they bind modified low-density-lipoprotein (LDL) cholesterol as normal.

241 ces (TMs) and three lumenal domains, exports low-density-lipoprotein (LDL)-derived cholesterol from l

242 ed candidate causal genes for schizophrenia, low-density-lipoprotein cholesterol and Crohn's disease.

243 Eight-week-old male low-density-lipoprotein-receptor-deficient mice were sub

244 ugh uptake of extracellular cholesterol from low density lipoproteins (LDL) via expression of LDL rec

245 eride (TAG)-rich lipoproteins including very low density lipoproteins (VLDLs) and chylomicrons, and r

246 Low-density lipoproteins (LDLs) are removed by extracorp

247 ntermediate-density lipoproteins (IDLs), and low-density lipoproteins (LDLs).

248 rol and triglycerides, respectively, in very low-density lipoproteins (VLDLs).

249 bolism, especially in the biogenesis of very low-density lipoproteins and chylomicrons via the transf

250 ody mass index, subcutaneous adipose tissue, low-density lipoproteins and total cholesterol levels).

251 ucing cardiovascular events, blood pressure, low-density lipoproteins, and adiposity-related outcomes

252 Binding to lipids was observed in liposomes, low-density lipoproteins, cell membranes, and plasma.

253 ated fatty acid intake (%SFA) and changes in low-density lipoproteins, high-density lipoproteins, and

254 e, including increases in total cholesterol, low-density lipoproteins, high-density lipoproteins, pho

255 ude the total level of cholesterol and high-/low-density lipoproteins, which often fails to accuratel

256 ntinuous structural change occurred in which low-density liquid domains appeared and grew on time sca

257 We introduce 'low-density' locality sensitive hashing to bioinformatic

258 l reefs, which declined to similar levels as low-density (<15 lionfish per 100 m(2)) artificial reefs

259 ion showed a lower proportion of medium- and low-density lung volume compared to patients on the norm

260 e gametocytes and sex ratios in asymptomatic low-density malaria infections are important for assessi

261 Low-density materials with tailorable properties have at

262 kinetic barrier for aggregate replication at low densities, meaning the change between prion or prion

263 d at growth fronts of the skeleton, within a low-density nano- or microporous layer varying in thickn

264 phene or graphene oxide is expected to yield low-density nanocomposites with exceptional mechanical p

265 Median NCP (147 vs 58, P < .001), low-density NCP (median 4.5 vs 0.9, P = .003), fibrous p

266 The accumulation of circulating low-density neutrophils (LDN) has been described in canc

267 trols, correlating with increased numbers of low-density neutrophils (LDNs) and neutrophil extracellu

268 wer to this puzzle and show that although at low densities, nucleosomes act as barriers to cohesin di

269 egetation height seismic lines in areas with low densities of anthropogenic features.

270 Factors affecting persistently low densities of generalist carnivores and piscivores ar

271 ical CO(2) reduction reaction (CRR), but the low density of active sites and the poor electrical cond

272 The low density of lignocellulose in the densified bamboo le

273 Low density of stromal CD4(+)FOXP3(+) TILs within TCe an

274 sin and elastase to penetrate regions with a low density of trypsin-cleavage sites.

275 a substantial elastic limit of 20-30% and a low density of ~1.4 g cm(-3).

276 e (tributyrin, 1,2,3-tributylglycerol) and a low-density oil (polydimethylsiloxane, PDMS) and describ

277 ermosensitive, degradable nanoparticles with low density, or hollow, cores.

278 tigen detection can inexpensively screen for low-density P. falciparum, non-falciparum, and Pfhrp2/3-

279 llumHD and AffyHD for the customization of a low-density panel increases the imputation accuracy for

280 gnostic tools for malaria but fail to detect low-density parasitemias that are important for maintain

281 The compression mechanism of the low-density phase involves increased molecular packing,

282 Low-density polyethylene and polycarbonate microplastic

283 Singapore that used an infrared-transparent, low-density polyethylene membrane to provide radiant coo

284 kable ability to consume and rapidly degrade low-density polyethylene.

285 ace and subsurface samples were dominated by low-density polypropylene particles, and sediment sample

286 across the DRG length, there was a distinct low density region in the outer 7-11% radially.

287 homogeneous compared to those in medium- and low-density regions.

288 ility and ductility, large elastic limit and low density represents a long-standing challenge, becaus

289 plastics have similar dispersion behavior to low density sediments.

290 em with very high quality (low disorder) and low density simultaneously.

291 Silica aerogels are low density solids with high surface area and high poros

292 ide important lessons for the development of low-density, stiff, and damage-tolerant cellular ceramic

293 Low-density stromal CD4(+)FOXP3(+) infiltrate within TCe

294 als are intriguing alternatives due to their low densities, structural and chemical versatility, and

295 The data presented here revealed low-density, termed hollow, nanoparticles (hNPs) load an

296 At low densities there is a clear linear relationship betwe

297 In such expansions, the low-density tip of the front grows much more slowly and

298 Low densities were found in the pallidum, hypothalamus,

299 high density when resources are scarce, and low densities when they are abundant, the variation in d

300 mental effects of stochastic processes (i.e. low densities where random bad years can cause local ext